Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.96 EUR | -0.67% | -6.33% | -8.64% |
2023 | Encres Dubuit Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | Encres Dubuit Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The stock, which is currently worth 2023 to 0.27 times its sales, is clearly overvalued in comparison with peers.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.64% | 9.68M | - | ||
+8.93% | 3.99B | D+ | ||
+4.74% | 1.77B | B+ | ||
+8.36% | 1.03B | - | D+ | |
+11.26% | 980M | - | ||
+74.92% | 789M | - | - | |
-5.93% | 668M | - | - | |
+2.08% | 569M | - | ||
+15.32% | 503M | - | ||
-2.76% | 418M | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- ALDUB Stock
- Ratings Encres DUBUIT